The role of cytomegalovirus in gut health and immune function in people with HIV
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
This study is looking at how cytomegalovirus (CMV) impacts the gut and immune system in people with chronic HIV, to see how it affects their health even when they're on treatment, and it will also check if stopping CMV helps improve gut health and immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11046509 on NIH RePORTER |
What this research studies
This research investigates how cytomegalovirus (CMV) affects the gastrointestinal tract and immune system in individuals living with chronic HIV infection. The study aims to understand how CMV contributes to the dysfunction of the gut barrier and ongoing immune activation, even in patients receiving antiretroviral therapy. Researchers will analyze tissue samples from participants to assess T-cell responses and the impact of CMV on immune function. Additionally, the study will explore the effects of suppressing CMV replication on gut health and immune markers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic HIV infection who may also have cytomegalovirus infection.
Not a fit: Patients who are not living with HIV or those who do not have a CMV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that enhance gut health and immune function in people living with HIV.
How similar studies have performed: Previous research has shown that targeting viral infections like CMV can improve immune function in HIV patients, suggesting potential success for this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Shacklett, Barbara L. — University of California at Davis
- Study coordinator: Shacklett, Barbara L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.